Jeffrey Calabrese - 29 Oct 2021 Form 3 Insider Report for AERIE PHARMACEUTICALS INC

Role: Vice President of Finance
Signature: s/ John LaRocca, Attorney-in-Fact for Jeffrey Calabrese
Issuer symbol: N/A
Transactions as of: 29 Oct 2021
Net transactions value: $0
Form type: 3
Filing time: 08 Nov 2021, 15:19:53 UTC
Next filing: 06 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AERI	Common Stock						8,019	29 Oct 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AERI	Stock Option (right to buy)							29 Oct 2021	Common Stock	14,400	$33.29	Direct	F1
holding	AERI	Stock Option (right to buy)							29 Oct 2021	Common Stock	7,200	$23.97	Direct	F2
holding	AERI	Stock Option (right to buy)							29 Oct 2021	Common Stock	6,257	$11.02	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These options have vested, or are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, with respect to 25% of the option on June 17, 2020, and monthly in substantially equal installments over the next 36 months thereafter.
F2	These options have vested, or are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in substantially equal installments on each of the first 48 monthly anniversaries of August 14, 2019.
F3	These options have vested, or are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in substantially equal installments on each of the first 48 monthly anniversaries of November 1, 2021.